查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2126375

胰臟癌診斷市場－策略分析與預測（2026-2035）

Pancreatic Cancer Diagnostics Market - Strategic Insights and Forecasts (2026-2035)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 177 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計胰臟癌診斷市場將從 2026 年的 42.6 億美元成長到 2035 年的 94.2 億美元，複合年成長率為 9.2%。

胰臟癌診斷市場正經歷重大變革，其驅動力在於早期檢測、精準腫瘤學和非侵入性診斷技術的模式轉移。該市場發展的一個關鍵特徵是，人們日益認知到及時準確的診斷對於提高生存率至關重要，因為胰腺癌通常在晚期才被確診，此時治療選擇有限。先進影像技術、分子診斷、液態生物檢體技術和人工智慧的整合，使得胰臟癌的檢測和發病機制研究能夠更快、更靈敏、更便捷地進行。隨著人口老化、生活方式因素以及慢性胰臟炎和糖尿病盛行率的上升，全球胰臟癌負擔持續加重，醫療系統正在不斷提升其診斷能力。對液態生物檢體平台、多生物標記檢測和伴隨診斷的大量投資，正在鞏固胰腺癌診斷作為胃腸腫瘤學和精準醫療關鍵組成部分的地位。

市場促進因素

  • 全球胰臟癌發生率的不斷上升是胰臟癌診斷市場的主要驅動力。日益加重的疾病負擔導致對診斷檢測的需求持續成長，這些檢測可用於篩檢、早期發現、診斷、治療方案選擇和疾病監測等應用。醫療系統正在擴展其診斷能力，以支持早期發現和個人化治療策略。這種需求推動了所有檢測方法的診斷產品需求，從而導致胰臟癌診斷市場持續擴張。人口老化和對癌症早期發現日益成長的需求進一步加速了市場成長。老年人罹患胰臟癌的風險更高，因此該族群對診斷檢測的需求持續增加。醫療機構正在擴大早期發現工作，以改善這種高致死率癌症的治療效果。診斷設備製造商正在開發專門的檢測解決方案，以支援早期發現專案。個人化醫療和伴隨診斷的日益普及推動了對分子譜分析和基因組檢測的需求。精準醫療需要準確的分子特徵分析來確定治療策略，因此對先進診斷技術的需求持續成長。醫療機構正在擴展其分子檢測能力，以支持個人化治療策略。診斷設備製造商正在開發專門的分子和基因組檢測解決方案，以支持精準腫瘤學的應用。分子診斷和基因組分析技術的進步正在提高診斷準確性和臨床效用。液態生物檢體、次世代定序(NGS) 和人工智慧輔助診斷技術的持續創新正在提高檢測的靈敏度和特異性。這些進步正在推動這些技術在臨床實踐中更廣泛的應用，並改善患者的治療效果。

市場限制因素

  • 先進分子診斷檢測的高成本限制了其在資源匱乏的醫療系統中的應用。先進技術所需的大量資金投入對小規模的醫療機構和發展中地區構成障礙。一些傳統生物標記檢測的敏感度有限，降低了臨床可靠性，阻礙了其推廣應用。某些生物標記的性能限制也為臨床實施帶來挑戰。新診斷產品嚴格的法規核准要求導致製造商的研發時間和成本增加。新診斷產品嚴格的證據要求也構成了市場准入障礙。某些市場對新興基因組檢測的保險報銷有限，限制了病患的取得和接受度。

對技術和模式的洞察

  • 技術發展趨勢的特徵是分子診斷、液態生物檢體和人工智慧平台的重要性日益凸顯。影像學檢查對於病灶檢測和疾病分期仍然至關重要。檢查室診斷和組織病理學檢查對於確診仍然必不可少。由於基因組分析、液態生物檢體和精準腫瘤學的廣泛應用，分子診斷正經歷最快的成長。分段分析表明，免疫組織化學仍然是腫瘤表徵和生物標記評估的核心技術。 PCR 繼續支持突變檢測和分子檢測。由於其在精準腫瘤學和全面基因組分析中的應用不斷擴展，NGS 已成為成長最快的技術。 EUS-FNA 仍然是組織樣本採集以進行病理學確診的黃金標準。免疫檢測繼續支持生物標記的檢測。 CA 19-9 仍然是胰腺癌檢測和後續觀察中最廣泛使用的生物標記。 KRAS 突變在治療選擇和精準腫瘤學中正變得越來越重要。 ctDNA正逐漸成為液態生物檢體應用中的重要生物標記。診斷仍然是其主要應用領域，在早期檢測和治療選擇方面發展迅速。醫院是主要的終端使用者群體，診斷檢查室和癌症中心也不斷擴展其檢測能力。隨著人工智慧驅動的影像和病理診斷技術提高診斷準確性和工作流程效率，人工智慧的整合變得日益重要。

競爭格局與策略展望

  • 在競爭激烈的市場格局中，除了成熟的診斷和生命科學公司外，還有專注於分子診斷、影像和精準癌症醫學的供應商。羅氏開發分子診斷、組織學診斷、伴隨診斷和病理學解決方案，以支持胰臟癌的精準診斷和治療選擇。賽默飛世爾科技開發PCR檢測、定序平台、分子診斷和精準癌症醫學技術，以支持胰臟癌檢測。丹納赫提供基因組技術、分子診斷、檢查室自動化和精準醫學解決方案，用於癌症診斷。雅培提供免疫檢測、臨床化學系統、分子診斷和生物標記檢測解決方案，以支持腫瘤診斷。西門子醫療提供先進的影像系統、檢查室診斷和數位醫療技術，以支援癌症診斷。安捷倫專注於用於腫瘤應用的病理解決方案、免疫組織化學檢測、基因組技術和伴隨診斷。 Illumina是領先的NGS平台供應商，其平台能夠實現全面的基因組分析和生物標記發現。凱傑公司致力於開發分子診斷檢測、PCR技術、檢體製備系統和伴隨診斷產品，以支持精準腫瘤學的發展。各公司都在透過在液態生物檢體、多生物標記檢測和人工智慧平台方面的創新來拓展產品系列。在伴隨診斷產品開發和精準腫瘤學解決方案需求的推動下，診斷設備製造商、製藥公司和研究機構之間的策略合作日益增加。近期的一些重要進展包括：Guardant Health公司擴展了其液態切片產品系列，增強了其在固體癌基因組分析方面的應用；Exact Sciences公司透過擴展其精準癌症檢測能力，強化了其分子腫瘤診斷產品線；羅氏公司宣布推出先進的伴隨診斷解決方案，以支持精準腫瘤學的發展；以及Illumina公司宣布推出先進的伴隨診斷解決方案，以支持精準腫瘤學的發展；以及Illumina 擴展了NGS應用分析以實現其全面的腫瘤基因組分析。

簡明結論

  • 胰臟癌診斷市場預計將持續成長，這主要得益於疾病負擔、技術創新以及精準醫療的融合。從傳統診斷方法向非侵入性、基於分子技術的整合策略的轉變，標誌著胃腸腫瘤學領域的根本性變革。儘管高成本、生物標記的敏感性以及監管要求等挑戰依然存在，但對技術、夥伴關係和臨床檢驗的策略性投資正為市場領導提供持續的競爭優勢。長期市場前景仍然樂觀，胰臟癌診斷正發展成為精準腫瘤學的重要組成部分，為全球醫療保健系統的早期檢測、治療選擇和患者預後改善提供支持。

本報告的主要益處：

  • 深入分析：詳細分析涵蓋各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業。
  • 競爭格局：我們將了解主要公司的策略部署，並確定最佳的市場進入方式。
  • 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
  • 實用建議：我們支援制定策略決策，以開發新的收入來源。
  • 適用於廣泛的使用者群體：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

你用它來做什麼？

    產業和市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發以及競爭影響。

分析範圍

  • 歷史資料（2021-2024 年）、基準年（2025 年）和預測資料（2026-2035 年）
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為和趨勢分析。
  • 競爭對手定位、策略和市場佔有率分析
  • 營收成長率及預測分析：依業務板塊及地區（國家）分類
  • 企業概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

  • 市場概述
  • 主要分析結果
  • 分析師意見
  • 策略建議

第2章 分析方法

  • 分析設計
  • 資料收集和分析方法
  • 市場規模估算
  • 預測模型
  • 先決條件和限制

第3章：全球胰臟癌診斷市場：概述、市場規模與預測

  • 市場定義和範圍
  • 行業概覽
  • 疾病演變與診斷趨勢
  • 主要市場趨勢
  • 實際成果值市場規模分析
  • 市場預測
  • 疾病盛行率分析
  • 已確診患者族群的分析
  • 胰臟癌診斷測試次數的分析。
  • 患者診斷路徑分析

第4章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰

第5章 行業情勢

  • 產業價值鏈分析
  • 定價分析
  • 還款狀態

第6章：創新趨勢

  • 新興技術
  • 產品創新
  • 液態生物檢體技術
  • 人工智慧在胰臟癌診斷的應用
  • 多組體學物標誌物的開發
  • 早期檢測技術
  • 技術藍圖

第7章 監理情勢

  • 法律規範
  • 核准流程
  • 合規要求

第8章：全球胰臟癌診斷市場：展望分析

  • 分析：按診斷方式
    • 診斷影像
    • 臨床試驗
    • 組織病理學
    • 分子診斷
  • 分析：按技術
    • 免疫組織化學（IHC）
    • 聚合酵素鏈鎖反應（PCR）
    • 次世代定序（NGS）
    • 超音波引導下細針穿刺切片檢查（EUS-FNA）
    • 免疫測量
  • 分析：透過生物標記
    • CA 19-9
    • 癌胚抗原（CEA）
    • KRAS突變
    • 循環腫瘤DNA（ctDNA）
    • 其他生物標記
  • 分析：透過臨床應用
    • 篩檢
    • 早期檢測
    • 診斷
    • 治療方案
    • 疾病監測

第9章 全球胰臟癌診斷市場：細分市場分析

  • 依產品
    • 裝置
    • 試劑和耗材
    • 軟體
  • 透過技術
    • 免疫組織化學（IHC）
    • 聚合酵素鏈鎖反應（PCR）
    • 次世代定序（NGS）
    • 超音波引導下細針穿刺切片檢查（EUS-FNA）
    • 免疫測量
    • 其他技術
  • 最終用戶
    • 醫院
    • 診斷檢查室
    • 癌症中心
    • 學術研究機構

第10章：全球胰臟癌診斷市場：區域分析

  • 北美洲
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東和非洲

第11章 全球胰臟癌診斷市場：國別分析

  • 美國
  • 加拿大
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 日本
  • 中國
  • 韓國
  • 印度
  • 澳洲
  • 巴西
  • 墨西哥
  • 沙烏地阿拉伯
  • 南非

第12章 競爭格局

  • 市佔率分析
  • 策略趨勢
  • 企業合併、商業夥伴關係和合作
  • 新產品發布

第13章：公司簡介

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • QIAGEN NV
  • Guardant Health, Inc.
  • Exact Sciences Corporation
  • Bio-Rad Laboratories, Inc.
  • Leica Biosystems
  • bioMerieux
  • Fujifilm Holdings Corporation
  • Sysmex Corporation

第14章 全球胰臟癌診斷市場：商業預測分析

第15章 投資與資金籌措分析

  • 創業投資趨勢
  • 政府資金
  • 研發投資

第16章：未來展望

  • 主要成長機遇
  • 未來產業趨勢
簡介目錄
Product Code: KSI-009087

The Pancreatic Cancer Diagnostics Market is set to reach USD 9.42 billion in 2035, growing at a CAGR of 9.2 % from USD 4.26 billion in 2026.

The pancreatic cancer diagnostics market is undergoing significant transformation driven by the paradigm shift toward early detection, precision oncology, and non-invasive diagnostic technologies. The market's evolution is characterized by the growing recognition that timely and accurate diagnosis is essential for improving survival outcomes, as pancreatic cancer is frequently diagnosed at advanced stages when therapeutic options are limited. The convergence of advanced imaging modalities, molecular diagnostics, liquid biopsy technologies, and artificial intelligence is enabling faster, more sensitive, and increasingly accessible pancreatic cancer detection and characterization. Healthcare systems worldwide are expanding diagnostic capabilities as the global burden of pancreatic cancer continues to rise due to aging populations, lifestyle factors, and increasing prevalence of chronic pancreatitis and diabetes. The market is witnessing significant investment in liquid biopsy platforms, multi-biomarker panels, and companion diagnostics, positioning pancreatic cancer diagnostics as a critical component of gastrointestinal oncology and precision medicine.

Market Drivers

  • The increasing global incidence of pancreatic cancer represents the primary driver for the pancreatic cancer diagnostics market. Rising disease burden creates sustained demand for diagnostic testing across screening, early detection, diagnosis, treatment selection, and disease monitoring applications. Healthcare systems are expanding diagnostic capacity to support early detection and personalized treatment strategies. This requirement strengthens demand for diagnostic products across all modalities, resulting in sustained growth in pancreatic cancer diagnostic utilization. The rising aging population and increasing demand for early cancer detection are further accelerating market growth. Older populations are at higher risk for pancreatic cancer, creating sustained demand for diagnostic testing among aging demographics. Healthcare providers are expanding early detection initiatives to improve outcomes for this high-mortality cancer. Diagnostic manufacturers are developing specialized testing solutions to support early detection programs. The growing adoption of personalized medicine and companion diagnostics is driving demand for molecular profiling and genomic testing. Precision medicine requires accurate molecular characterization to guide therapeutic decisions, creating sustained demand for advanced diagnostic technologies. Healthcare providers are expanding molecular testing capabilities to support personalized treatment strategies. Diagnostic manufacturers are developing specialized molecular and genomic testing solutions to support precision oncology applications. Technological advancements in molecular diagnostics and genomic profiling are improving diagnostic accuracy and clinical utility. Continuous innovation in liquid biopsy, NGS, and AI-assisted diagnostics is enhancing detection sensitivity and specificity. These advancements support broader clinical adoption and improved patient outcomes.

Market Restraints

  • High costs associated with advanced molecular diagnostic testing limit adoption in resource-constrained healthcare systems. The significant financial investment required for advanced technologies creates barriers for smaller facilities and developing regions. Limited sensitivity of some conventional biomarker assays reduces clinical confidence and adoption. The performance limitations of certain biomarkers create challenges for clinical implementation. Stringent regulatory approval requirements for novel diagnostics increase development timelines and costs for manufacturers. The rigorous evidence requirements for new diagnostic products create barriers to market entry. Limited reimbursement for emerging genomic testing in certain markets restricts patient access and adoption.

Technology and Modality Insights

  • The technology landscape is characterized by the growing importance of molecular diagnostics, liquid biopsy, and AI-enabled platforms. Imaging diagnostics remain essential for lesion detection and disease staging. Laboratory diagnostics and histopathology remain essential for diagnosis confirmation. Molecular diagnostics are experiencing the fastest growth due to increasing adoption of genomic profiling, liquid biopsy, and precision oncology. The segment analysis reveals that immunohistochemistry remains a cornerstone technology for tumor characterization and biomarker evaluation. PCR continues to support mutation detection and molecular testing. NGS is the fastest-growing technology owing to expanding precision oncology applications and comprehensive genomic profiling. EUS-FNA remains the gold standard for obtaining tissue samples for pathological confirmation. Immunoassays continue to support biomarker detection. CA 19-9 remains the most widely utilized biomarker for pancreatic cancer detection and monitoring. KRAS mutations are increasingly important for treatment selection and precision oncology. ctDNA is emerging as a key biomarker for liquid biopsy applications. Diagnosis remains the primary application, with early detection and treatment selection experiencing rapid growth. Hospitals represent the leading end-user segment, with diagnostic laboratories and cancer centers expanding testing capabilities. The integration of AI is becoming increasingly important as AI-assisted imaging and pathology improve diagnostic accuracy and workflow efficiency.

Competitive and Strategic Outlook

  • The competitive landscape features established diagnostics and life science companies alongside specialized molecular, imaging, and precision oncology providers. Roche develops molecular diagnostics, tissue diagnostics, companion diagnostics, and pathology solutions supporting precision diagnosis and treatment selection in pancreatic cancer. Thermo Fisher Scientific develops PCR assays, sequencing platforms, molecular diagnostics, and precision oncology technologies supporting pancreatic cancer testing. Danaher offers genomics technologies, molecular diagnostics, laboratory automation, and precision medicine solutions for cancer diagnostics. Abbott provides immunoassays, clinical chemistry systems, molecular diagnostics, and biomarker testing solutions supporting oncology diagnostics. Siemens Healthineers offers advanced imaging systems, laboratory diagnostics, and digital healthcare technologies supporting cancer diagnosis. Agilent specializes in pathology solutions, immunohistochemistry assays, genomic technologies, and companion diagnostics for oncology applications. Illumina is a leading provider of NGS platforms enabling comprehensive genomic profiling and biomarker discovery. QIAGEN develops molecular diagnostic assays, PCR technologies, sample preparation systems, and companion diagnostics supporting precision oncology. Companies are pursuing product portfolio expansion through innovation in liquid biopsy, multi-biomarker panels, and AI-enabled platforms. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for companion diagnostic development and precision oncology solutions. Recent key developments include Guardant Health expanding its liquid biopsy portfolio with enhanced genomic profiling applications for solid tumors. Exact Sciences strengthened its molecular oncology diagnostics pipeline through expanded precision cancer testing capabilities. Roche introduced advanced companion diagnostic solutions supporting precision oncology. Illumina expanded NGS applications for comprehensive oncology genomic profiling.

Short Conclusion

  • The pancreatic cancer diagnostics market is positioned for sustained growth driven by the convergence of disease burden, technological innovation, and precision medicine. The transition from conventional diagnostic approaches toward integrated non-invasive and molecular strategies represents a fundamental shift in gastrointestinal oncology. While challenges related to high costs, biomarker sensitivity, and regulatory requirements persist, strategic investments in technology, partnerships, and clinical validation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with pancreatic cancer diagnostics evolving into a critical component of precision oncology, supporting early detection, treatment selection, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

  • Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Market Snapshot
  • 1.2 Key Findings
  • 1.3 Analyst Insights
  • 1.4 Strategic Recommendations

2. Research Methodology

  • 2.1 Research Design
  • 2.2 Data Collection Methodology
  • 2.3 Market Size Estimation
  • 2.4 Forecasting Model
  • 2.5 Assumptions & Limitations

3. Global Pancreatic Cancer Diagnostics Market Overview, Size & Forecast

  • 3.1 Market Definition & Scope
  • 3.2 Disease Overview
  • 3.3 Disease Evolution and Diagnostic Landscape
  • 3.4 Key Market Trends
  • 3.5 Historical Market Size Analysis (2021-2025)
  • 3.6 Market Forecast (2026-2035)
  • 3.7 Disease Prevalence Analysis
  • 3.8 Diagnosed Patient Population Analysis
  • 3.9 Pancreatic Cancer Diagnostic Testing Volume Analysis
  • 3.10 Patient Diagnostic Pathway Analysis

4. Market Dynamics

  • 4.1 Market Drivers
  • 4.2 Market Restraints
  • 4.3 Market Opportunities
  • 4.4 Market Challenges

5. Industry Landscape

  • 5.1 Industry Value Chain Analysis
  • 5.2 Pricing Analysis
  • 5.3 Reimbursement Landscape

6. Innovation Landscape

  • 6.1 Emerging Technologies
  • 6.2 Product Innovation
  • 6.3 Liquid Biopsy Technologies
  • 6.4 Artificial Intelligence in Pancreatic Cancer Diagnostics
  • 6.5 Multi-Omics Biomarker Development
  • 6.6 Early Detection Technologies
  • 6.7 Technology Roadmap

7. Regulatory Landscape

  • 7.1 Regulatory Framework
  • 7.2 Approval Pathways
  • 7.3 Compliance Requirements

8. Global Pancreatic Cancer Diagnostics Market Landscape Analysis

  • 8.1 Analysis by Diagnostic Modality
    • 8.1.1 Imaging Diagnostics
    • 8.1.2 Laboratory Diagnostics
    • 8.1.3 Histopathology
    • 8.1.4 Molecular Diagnostics
  • 8.2 Analysis by Technology
    • 8.2.1 Immunohistochemistry (IHC)
    • 8.2.2 Polymerase Chain Reaction (PCR)
    • 8.2.3 Next-Generation Sequencing (NGS)
    • 8.2.4 Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA)
    • 8.2.5 Immunoassays
  • 8.3 Analysis by Biomarker
    • 8.3.1 CA 19-9
    • 8.3.2 Carcinoembryonic Antigen (CEA)
    • 8.3.3 KRAS Mutations
    • 8.3.4 Circulating Tumor DNA (ctDNA)
    • 8.3.5 Other Biomarkers
  • 8.4 Analysis by Clinical Application
    • 8.4.1 Screening
    • 8.4.2 Early Detection
    • 8.4.3 Diagnosis
    • 8.4.4 Treatment Selection
    • 8.4.5 Disease Monitoring

9. Global Pancreatic Cancer Diagnostics Market Segment Analysis (2021-2035)

  • 9.1 By Product
    • 9.1.1 Instruments
    • 9.1.2 Reagents & Consumables
    • 9.1.3 Software
  • 9.2 By Technology
    • 9.2.1 Immunohistochemistry (IHC)
    • 9.2.2 Polymerase Chain Reaction (PCR)
    • 9.2.3 Next-Generation Sequencing (NGS)
    • 9.2.4 Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA)
    • 9.2.5 Immunoassays
    • 9.2.6 Other Technologies
  • 9.3 By End User
    • 9.3.1 Hospitals
    • 9.3.2 Diagnostic Laboratories
    • 9.3.3 Cancer Centers
    • 9.3.4 Academic & Research Institutes

10. Global Pancreatic Cancer Diagnostics Market Geographical Analysis (2021-2035)

  • 10.1 North America
  • 10.2 Europe
  • 10.3 Asia-Pacific
  • 10.4 South America
  • 10.5 Middle East & Africa

11. Global Pancreatic Cancer Diagnostics Market Country Analysis (2021-2035)

  • 11.1 United States
  • 11.2 Canada
  • 11.3 Germany
  • 11.4 United Kingdom
  • 11.5 France
  • 11.6 Italy
  • 11.7 Spain
  • 11.8 Japan
  • 11.9 China
  • 11.10 South Korea
  • 11.11 India
  • 11.12 Australia
  • 11.13 Brazil
  • 11.14 Mexico
  • 11.15 Saudi Arabia
  • 11.16 South Africa

12. Competitive Landscape

  • 12.1 Market Share Analysis
  • 12.2 Strategic Developments
  • 12.3 Mergers & Acquisitions, Partnerships & Collaborations
  • 12.4 Product Launches

13. Company Profiles

  • 13.1 F. Hoffmann-La Roche Ltd.
    • 13.1.1 Company Overview
    • 13.1.2 Financials
    • 13.1.3 Product Portfolio
    • 13.1.4 Recent Developments
  • 13.2 Thermo Fisher Scientific Inc.
    • 13.2.1 Company Overview
    • 13.2.2 Financials
    • 13.2.3 Product Portfolio
    • 13.2.4 Recent Developments
  • 13.3 Danaher Corporation
    • 13.3.1 Company Overview
    • 13.3.2 Financials
    • 13.3.3 Product Portfolio
    • 13.3.4 Recent Developments
  • 13.4 Abbott Laboratories
    • 13.4.1 Company Overview
    • 13.4.2 Financials
    • 13.4.3 Product Portfolio
    • 13.4.4 Recent Developments
  • 13.5 Siemens Healthineers AG
    • 13.5.1 Company Overview
    • 13.5.2 Financials
    • 13.5.3 Product Portfolio
    • 13.5.4 Recent Developments
  • 13.6 Agilent Technologies, Inc.
    • 13.6.1 Company Overview
    • 13.6.2 Financials
    • 13.6.3 Product Portfolio
    • 13.6.4 Recent Developments
  • 13.7 Illumina, Inc.
    • 13.7.1 Company Overview
    • 13.7.2 Financials
    • 13.7.3 Product Portfolio
    • 13.7.4 Recent Developments
  • 13.8 QIAGEN N.V.
    • 13.8.1 Company Overview
    • 13.8.2 Financials
    • 13.8.3 Product Portfolio
    • 13.8.4 Recent Developments
  • 13.9 Guardant Health, Inc.
    • 13.9.1 Company Overview
    • 13.9.2 Financials
    • 13.9.3 Product Portfolio
    • 13.9.4 Recent Developments
  • 13.10 Exact Sciences Corporation
    • 13.10.1 Company Overview
    • 13.10.2 Financials
    • 13.10.3 Product Portfolio
    • 13.10.4 Recent Developments
  • 13.11 Bio-Rad Laboratories, Inc.
    • 13.11.1 Company Overview
    • 13.11.2 Financials
    • 13.11.3 Product Portfolio
    • 13.11.4 Recent Developments
  • 13.12 Leica Biosystems
    • 13.12.1 Company Overview
    • 13.12.2 Financials
    • 13.12.3 Product Portfolio
    • 13.12.4 Recent Developments
  • 13.13 bioMerieux
    • 13.13.1 Company Overview
    • 13.13.2 Financials
    • 13.13.3 Product Portfolio
    • 13.13.4 Recent Developments
  • 13.14 Fujifilm Holdings Corporation
    • 13.14.1 Company Overview
    • 13.14.2 Financials
    • 13.14.3 Product Portfolio
    • 13.14.4 Recent Developments
  • 13.15 Sysmex Corporation
    • 13.15.1 Company Overview
    • 13.15.2 Financials
    • 13.15.3 Product Portfolio
    • 13.15.4 Recent Developments

14. Global Pancreatic Cancer Diagnostics Market Commercial Forecast Analysis

  • 14.1 Imaging Diagnostics
  • 14.2 Histopathology-Based Diagnostics
  • 14.3 Molecular Diagnostic Tests
  • 14.4 CA 19-9 Diagnostic Tests
  • 14.5 Liquid Biopsy Tests
  • 14.6 Next-Generation Sequencing (NGS)-Based Tests
  • 14.7 Endoscopic Ultrasound-Guided Diagnostic Technologies

15. Investment & Funding Analysis

  • 15.1 Venture Capital Trends
  • 15.2 Government Funding
  • 15.3 R&D Investments

16. Future Outlook

  • 16.1 Key Growth Opportunities
  • 16.2 Future Industry Trends